Standardization of DC generation
Laboratory protocol
Argos successfully developed a manual DC manufacturing method with excellent reproducibility in terms of quality, yield, and viability of DCs. The process developed has the following unique advantages:
- The manufacturing process has been optimized for producing DC from non-frozen day-old pheresis material which allows centralized manufacturing. The pheresis product is sent in a specially designed shipper to the manufacturing facility.
- The final vaccine product is formulated for direct injection (i.e., no clinical site participation required except for bedside thaw and i.d. injection)

- biomaterial type
- dendritic cell
created over 16 years ago
(2 March 2009)
last modified over 14 years ago
(28 September 2011)
 [ RDF ]
 [ RelFinder
]